Thus, the restricted expression profile of STEAP2 may minimize the risk of off-tumor, on-target sink tissues and potential toxicities, compared with the gastrointestinal tract, brain, liver, and kidney expression seen with PSMA (10, 23–26). Here, STEAP2 is linked to neoplasm.